Karuna, Cerevel Might Be Just the Start of Psychiatry Drug M&A

AbbVie and Bristol Myers Squibb each capped last year with multibillion-dollar acquisitions of companies developing new drugs for psychiatric conditions. But they weren’t the only interested buyers, according to recently disclosed deal details, suggesting to some analysts that more tie-ups could transpire. While many larger pharmaceutical firms have either dismissed or deprioritized research into diseases of the brain, scientific breakthroughs are luring some back and others to invest more meaningfully. Now, with the proposed buyouts of Karuna Therapeutics and Cerevel Therapeutics, neuropsychiatry appears to be in the spotlight.

Read the full article: Karuna, Cerevel Might Be Just the Start of Psychiatry Drug M&A //

Source: https://www.biopharmadive.com/news/schizophrenia-pharma-karuna-cerevel-deal-bidders/704522

Leave a Comment

Your email address will not be published.

Scroll to Top